Dual-Pathway Inhibition with Rivaroxaban and Low-Dose Aspirin Does Not Alter Immune Cell Responsiveness and Distribution in Patients with Coronary Artery Disease

Dual-Pathway Inhibition with Rivaroxaban and Low-Dose Aspirin Does Not Alter Immune Cell Responsiveness and Distribution in Patients with Coronary Artery Disease

Abstract Introduction Cardiovascular diseases (CVD) are the leading cause of death globally. Inflammation is an important driver of CVD where tissue damage may lead to the formation of deadly thrombi. Therefore, antithrombotic drugs, such as platelet inhibitors, are crucial for secondary risk preven...

Full description

Bibliographic Details
Main Authors: Laszlo A. Groh, Loes H. Willems, Paula Fintelman, Michel M. P. J. Reijnen, Saloua El Messaoudi, Michiel C. Warlé
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-12-01
Series:Cardiology and Therapy
Subjects:
Inflammation
Cardiovascular diseases
Platelet aggregation inhibitors
Factor Xa inhibitors
Immunity
Online Access:https://doi.org/10.1007/s40119-023-00342-5

Internet

https://doi.org/10.1007/s40119-023-00342-5

Similar Items